Skip to main navigation Skip to search Skip to main content

Time to castration resistance is an independent predictor of castration-resistant prostate cancer survival

  • Evangelos Bournakis
  • , Eleni Efstathiou
  • , Andreas Varkaris
  • , Sijin Wen
  • , Michael Chrisofos
  • , Charalambos Deliveliotis
  • , Christos Alamanis
  • , Ioannis Anastasiou
  • , Constantine Constantinides
  • , Aristotelis Bamias
  • , Meletios A. Dimopoulos

Research output: Contribution to journal › Article › peer-review

Abstract

Background/Aim: Easily assessable clinical predictors of response to chemotherapy in advanced castration-resistant prostate cancer (CRPC) are few. The objective of this retrospective study was to search for and identify such candidate predictors of outcome. Patients and Methods: A retrospective analysis of clinical data of CRPC patients entered in the Clinical Therapeutics' departmental prostate cancer database from 1996-2009 was performed. Univariate and multivariate analyses for progression-free survival and overall survival included patients receiving both docetaxel- and non-docetaxel-containing regimens. Results: From 1996 until June 2009, 286 out of 313 patients in our database were treated with chemotherapy. Prostate-specific antigen (PSA) reduction >30% correlated with improved survival irrespective of treatment. Beyond previously reported predictors, i.e. baseline PSA>30 ng/dl, hemoglobin below 10 mg/dl, weight loss, poor performance status, elevated lactic dehydrogenase and alkaline phosphatase, and time to CRPC of less than or equal to two years was associated with a poor overall survival and shorter progression-free survival upon univariate analysis. Pain was associated with shorter survival. Multivariate analysis confirmed time to CRPC, lactate dehydrogenase and alkaline phosphatase as independent predictors of overall and progression-free survival. Conclusion: Time to castration resistance is an important predictor of outcome in CRPC. PSA reduction >30% predicts survival improvement following chemotherapy for CRPC regardless of chemotherapy applied.

Original languageEnglish (US)
Pages (from-to)1475-1482
Number of pages8
JournalAnticancer research
Volume31
Issue number4
StatePublished - Apr 2011

Keywords

  • Advanced prostate cancer
  • Castrate-resistant prostate cancer
  • Chemotherapy
  • Predictors of survival
  • Time to castration resistance

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Time to castration resistance is an independent predictor of castration-resistant prostate cancer survival'. Together they form a unique fingerprint.

Cite this